(12) **Translation of European patent specification**

(11) **NO/EP 3095463 B1**

NORWAY

(19) NO

(51) Int Cl.

A61K 45/06 (2006.01)
A61B 5/055 (2006.01)
A61K 9/00 (2006.01)
A61K 39/00 (2006.01)
A61K 39/395 (2006.01)
C07K 16/28 (2006.01)
G01N 33/68 (2006.01)
G06Q 99/00 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2020.11.16
(80)	Date of The European Patent Office Publication of the Granted Patent	2020.09.09
(86)	European Application Nr.	16151683.6
(86)	European Filing Date	2009.09.16
(87)	The European Application's Publication Date	2016.11.23
(30)	Priority	2008.09.16, US, 97464 P
(84)	Designated Contracting States:	AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel, Sveits
(72)	Inventor	SMITH, Craig, 1507, 42nd Avenue East, Seattle, WA 98112, USA CHIN, Peter S., 855 Folsom Street, Unit 329, San Francisco, CA 94107, USA
(74)	Agent or Attorney	PLOUGMANN VINGTOFT, Postboks 1003 Sentrum, 0104 OSLO, Norge

(54) Title **METHODS FOR TREATING PROGRESSIVE MULTIPLE SCLEROSIS**

(56) References Cited:

WO-A-2005/117978 MONSON NANCY L ET AL: "EFFECT OF RITUXIMAB ON THE PERIPHERAL BLOOD AND CEREBROSPINAL FLUID B CELLS IN PATIENTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS", ARCHIVES OF NEUROLOGY, AMERICAN MEDICAL ASSOCIATION, CHICAGO, IL, US, vol. 62, no. 2, 1 February 2005 (2005-02-01), pages 258-264, XP009085313, ISSN: 0003-9942

HAWKER K: "B-cell-targeted treatment for multiple sclerosis: Mechanism of action and clinical data", CURRENT OPINION IN NEUROLOGY, RAPID SCIENCE PUBLISHERS, LONDON, GB, vol. 21, no. SUPPL 1, 1 April 2008 (2008-04-01), pages S19-S25, XP008102094, ISSN: 1350-754HAWKER KS ET AL: "Efficacy and safety of rituximab in patients with primaryprogressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, multicenter trial",

MULTIPLE SCLEROSIS, SAGE PUBLICATIONS, BASINGSTOKE, GB, vol. 14, 26 August 2008

(2008-08-26), page S299, XP009128819, ISSN: 1352-4585
HAUSER STEPHEN L ET AL: "B-cell depletion with Rituximab in relapsing-remitting multiple sclerosis", NEW ENGLAND JOURNAL OF MEDICINE, vol. 358, no. 7, February 2008 (2008-02), pages 676-688, XP002567454, ISSN: 0028-4793
BAR-OR AMIT ET AL: "Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial", ANNALS OF NEUROLOGY, vol. 63, no. 3, March 2008 (2008-03), pages 395-400, XP002567455, ISSN: 0364-5134
CROSS A H ET AL: "Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients", JOURNAL OF NEUROIMMUNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, XX, vol. 180, no. 1-2, 1 November 2006 (2006-11-01), pages 63-70, XP025039481, ISSN: 0165-5728 [retrieved on 2006-11-01]
MCDONALD W I ET AL: "RECOMMENDED DIAGNOSTIC CRITERIA FOR MULTIPLE SCLEROSIS: GUIDELINES FROM THE INTERNATIONAL PANEL ON THE DIAGNOSIS OF MULTIPLE SCLEROSIS", ANNALS OF NEUROLOGY, JOHN WILEY AND SONS, BOSTON, US, vol. 50, no. 1, 1 July 2001 (2001-07-01), pages 121-127, XP009053064, ISSN: 0364-5134
ROXBURGH R H S R ET AL: "Multiple sclerosis severity score - Using disability and disease duration to rate disease severity", NEUROLOGY, vol. 64, no. 7, April 2005 (2005-04), pages 1144-1151, XP002567456, ISSN: 0028-3878
GROUIN J -M ET AL: "Subgroup analyses in randomized clinical trials: Statistical and regulatory issues", JOURNAL OF BIOPHARMACEUTICAL STATISTICS 2005 US, vol. 15, no. 5, 2005, pages 869-882, XP009129300,
WANG RUI ET AL: "Statistics in medicine - Reporting of subgroup analyses in clinical trials", NEW ENGLAND JOURNAL OF MEDICINE, vol. 357, no. 21, November 2007 (2007-11), pages 2189-2194, XP002567458, ISSN: 0028-4793
WOLINSKY JERRY S ET AL: "Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial", ANNALS OF NEUROLOGY, vol. 61, no. 1, January 2007 (2007-01), pages 14-24, XP002567459, ISSN: 0364-5134
HAWKER KATHLEEN ET AL: "Rituximab in Patients with Primary Progressive Multiple Sclerosis Results of a Randomized Double-Blind Placebo-Controlled Multicenter Trial", ANNALS OF NEUROLOGY, vol. 66, no. 4, 9 September 2009 (2009-09-09), pages 460-471, XP002567460, ISSN: 0364-5134
HARTUNG HANS-PETER ET AL: "Bleak prospects for primary progressive multiple sclerosis therapy: downs and downs, but a glimmer of hope.", ANNALS OF NEUROLOGY OCT 2009, vol. 66, no. 4, October 2009 (2009-10), pages 429-432, XP009129053, ISSN: 1531-8249
PETEREIT HELA-F ET AL: "EFFECTIVE SUPPRESSION OF CEREBROSPINAL FLUID B CELLS BY RITUXIMAB AND CYCLOPHOSPHAMIDE IN PROGRESSIVE MULTIPLE SCLEROSIS", ARCHIVES OF NEUROLOGY, AMERICAN MEDICAL ASSOCIATION, CHICAGO, IL, US, vol. 62, no. 10, 1 October 2005 (2005-10-01), pages 1641-1642, XP009085305, ISSN: 0003-9942

PATENTKRAV

1. Okrelizumab for anvendelse ved behandling av multippel sklerose hos en pasient, hvori en effektiv mengde av okrelizumab administreres til pasienten for å tilveiebringe en første eksponering for okrelizumab på 0,6 gram og deretter en andre eksponering for okrelizumab på 0,6 gram, hvori den første eksponeringen for okrelizumab omfatter en første dose og en andre dose okrelizumab, hvori den første dosen og den andre dosen av okrelizumab hver er 0,3 gram, hvori den andre dosen gis 14 dager etter den første dosen, hvori den andre eksponeringen for okrelizumab tilveiebringes omtrent 24 uker etter den første eksponeringen, og hvori den andre eksponeringen for okrelizumab omfatter en enkeltdose av okrelizumab, hvori enkeltdosen av okrelizumab er 0,6 gram.

2. Okrelizumab for anvendelse ved behandling av multippel sklerose ifølge krav 1, videre omfattende å tilveiebringe en tredje eksponering for okrelizumab.

3. Okrelizumab for anvendelse ved behandling av multippel sklerose ifølge krav 2, videre omfattende å tilveiebringe en fjerde eksponering for okrelizumab.

4. Okrelizumab for anvendelse ved behandling av multippel sklerose ifølge krav 3, videre omfattende å tilveiebringe en femte eksponering for okrelizumab.